A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
← catalyst calendarSponsored by Xenon Pharmaceuticals Inc. (industry) · XENE — their whole pipeline →. With Novotech Health Holdings Pte. Ltd..
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
325actual
Sites
95
Countries
Canada, Georgia, Germany +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-01-30 | actual | When the study began enrolling |
| Primary completion | 2021-09-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2019-01-08 | actual | When this record first appeared on the registry |
| Results posted | 2024-09-24 | actual | When the sponsor posted results to the registry |
| Record updated | 2024-09-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Focal Epilepsy
Intervention
- Drug: XEN1101
Primary outcome
what the primary-completion date above is the date OFMedian Percent Change in Focal Seizure Frequency
measured From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocol and Statistical Analysis Planposted 2021-01-22 · 1.5 MB · Prot_SAP_001.pdf
Publications
- PMID 37812429 — reports results
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · XENE's whole pipeline · Catalyst calendar · Every registered study · What changed